Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EMBARK

- PMLiVE

Astellas sets up regenerative medicine unit

Will spearhead company's efforts in cell-based therapies

Otsuka’s Samsca heads clutch of Japanese approvals

Astellas' Xtandi, AstraZeneca's Forxiga and Takeda's Zacras also given the green light

National Institute for Health and Care Excellence NICE logo

Mixed cancer news from NICE

Agency backs Janssen’s myeloma drug but denies Bayer’s Xofigo in prostate cancer

- PMLiVE

Xtandi filed as pre-chemo prostate cancer therapy

Astellas and Medivation look to extend uses of their prostate cancer drug

EU flag

European Commission sets out HIV/Aids action plan

Says two-year programme proves HIV/Aids remains an EU health policy priority

mHealth could be ‘the future’ of healthcare

EC says Europe is preparing for the mHealth revolution

- PMLiVE

NICE backs Astellas’ Xtandi in prostate cancer

But company criticises restrictions imposed by HTA body for England

- PMLiVE

Ipragliflozin beats diabetes rivals to Japanese approval

Astellas drug is first SGLT2 inhibitor backed by country’s regulator

- PMLiVE

Astellas boosts vaccine ambitions

Forms alliance with ClearPath Development

- PMLiVE

The oncology market in Canada

Ten per cent is not enough - simple estimates of the Canadian oncology market overlook a complex picture

Bayer symbol

EU approval for Bayer’s prostate cancer drug

Xofigo wins marketing authorisation from European Commission

- PMLiVE

AZ invests £120m in UK cancer drug production

New facility in Macclesfield to manufacture Zoladex will retain 300 jobs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links